Abstract:Abstract Background Transcatheter mitral valve-in-valve (TMVIV) appears a reasonable alternative to surgical redo mitral valve replacement in patients with degenerated mitral prosthesis and high surgical risk with favorable early and mid-terms outcomes. Long-term outcomes are limited by high mortality in a comorbid population. Purpose We aimed to evaluate early prosthesis hemodynamic performance and late clinical outcomes following TMVIV. Methods All patients who underwent TMVIV for degenerated surgical mitral bioprostheses from 2011 to 2020 in our center were included. Prospectively collected demographic, clinical, procedural, and imaging variables were analyzed. Clinical and echocardiographic outcomes were defined according to Mitral Valve Academic Research Consortium (MVARC) definitions and assessed at 30-day and at the latest follow-up available. Results A total of 67 patients were included; mean age 76.9±9.6 years, mean STS score 11.0±6.2%, 53.7% male (n=36). Mechanisms of bioprosthetic failure were mitral stenosis (n=32, 47.8%), mitral regurgitation (n=24, 35.8%), and mixed (n=11, 16.4%). Mean time from mitral valve surgery to TMVIV was 10.2±4.3 years. Access was mostly transapical (n=45; 67.2%), followed by transseptal (n=22; 32.8%). Following the first transseptal procedure in 2016; transseptal access accounted for the majority of procedures (22 of 37 cases, 59.4%). Technical success was achieved in 65 patients (97.0%). Mean hospitalization was 9.2±10.0 days; shorter with the transseptal as opposed to the transapical approach (6.3±8.1 days versus 11.0±10.5 days, p=0.001). At 30-day echographic follow-up, mean mitral valve gradient was 7.3±2.7 and 1 patient (1.9%) had mitral regurgitation >mild. At 30-day follow-up, 3 patients had died (4.5%); due to left ventricular outflow tract obstruction (1), heart failure (1), and stroke (1). New pacemakers were required in 2 patients (3.0%) and pacemaker lead dislodgement occurred in 1 patient (1.5%), 4 patients (6.2%) were hospitalized for heart failure. At a median follow-up of 3.8 years [1.7–5.1], 29 patients had died (43.3%), valve thrombosis was found in 6 (8.9%) and endocarditis in 4 patients (6.2%). Mitral valve reintervention was performed in 4 patients (6.2%); redo TMVIV due to valve migration in 1 (1.9%), surgical valve replacement in 1 (1.9%), and delayed redilation with a non-compliant balloon due to underexpansion in 2 patients (3.8%). Conclusion TMVIV is associated with acceptable 30-day mitral valve hemodynamics. Long-term mortality remains high in this high-surgical risk comorbid group. Funding Acknowledgement Type of funding sources: None.

800.56 Transseptal Transcatheter Mitral Valve Replacement with AltaValve: A Single-Center Experience

800.52 AltaValve TMVR for the Treatment of Patients with Severe Mitral Regurgitation and Mitral Annular Calcification

Current Status of Catheter-based Mitral Valve Replacement

Initial Experience of Transcatheter Mitral Valve Replacement With a Novel Transcatheter Mitral Valve: Procedural and 6-Month Follow-Up Results

Outcomes Following Transcatheter Mitral Valve Replacement Using Dedicated Devices in Patients With Mitral Annular Calcification

800.55 Patients with Low Cardiac Index Treated with Atrial Fixation TMVR

Transcatheter mitral valve-in-valve implantation: a 10-year single center experience

Percutaneous Transcatheter Mitral Valve Replacement: First-in-Human Experience With a New Transseptal System

Direct Implantation of Transcatheter Valve in Mitral Annular Calcification: A Multi-Center Study

Transcatheter Mitral Valve Repair or Replacement: Competitive or Complementary?

Outcomes after transcatheter mitral valve implantation in valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification

Transcatheter Mitral Valve Replacement Using Annular Reduction by Cinching With TEER in the Commissure (ARCTIC)

Transcatheter mitral valve implantation via transapical approach: an early experience

Transcatheter mitral valve replacement to treat rheumatic mitral stenosis: a case series

Current status and future prospect of transcatheter mitral valve replacement

800.54 Outcomes of Transcatheter Mitral Valve Replacement with Sapien Transcatheter Heart Valve for Degenerated Bioprostheses and Failed Annuloplasty Rings: A Meta-Analysis

Clinical and haemodynamic outcomes of balloon-expandable transcatheter mitral valve implantation: a 7-year experience

800.51 Early Feasibility of the Innovalve TMVR: 1-Year Follow-Up Data from TWIST-EFS and TWIST-OUS Studies

First-in-Human Study of the Novel Transcatheter Mitral Valve Repair System for Mitral Regurgitation.

Impact and limitations of 3D computational modelling in transcatheter mitral valve replacement-a two-centre Dutch experience

Transcatheter mitral valve implantation for inoperable severely calcified native mitral valve disease: A systematic review